HD204

DRUG2 trials

Sponsors

Prestige Biopharma Limited

Conditions

Healthy VolunteersLung CancerNon-small Cell Lung Cancer

Phase 1

To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

CompletedNCT03390673

Prestige Biopharma LimitedHealthy Volunteers

Start: 2018-09-19End: 2019-03-13Updated: 2026-07-29

Phase 3

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Active, not recruitingNCT03390686

Prestige Biopharma LimitedLung Cancer, Non-small Cell Lung Cancer

Start: 2019-11-15End: 2025-12-31Updated: 2025-05-31

Related Papers

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

2021-09-233 citations